Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Oligometastatic breast cancer: old to new entity, outcome and treatment algorithm

BGICC 2023

19 - 20 Jan 2023

Published: 31 Jan 2023

Views: 49

Rating:

Save

Prof Sandra Swain - Georgetown University Medical Center, Washington DC, USA

Prof Sandra Swain speaks to ecancer at BGICC 2023 about oligometastatic breast cancer.

She defines the term oligometastatic as the intermediate step between primary breast cancer and metastatic breast cancer and then highlights the theoretical approaches which surround this term.

Prof Swain also outlines key randomised breast cancer studies presented in her BGICC 2023 talk such as the ongoing OLIGOMA trial.

Related Videos

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy...

Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia

Upfront [177Lu]Lu-PSMA-617 radioligand therapy prior to radical prostatectomy in men with HR PC ( Dr Renu Eapen - Peter MacCallum Cancer Centre, Melbourne, Australia )

IORT at the Asian Hospital and Medical Center

Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines

IORT at the Asian Hospital and Medical Center ( Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines )

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast...

Dr Jayant Vaidya - University College London, London, UK

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in...

Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC ( Dr Laurence Albiges - Institut Gustave Roussy, Villejuif, France )

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Moving to the future: Artificial intelligence in surgery

Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal

Moving to the future: Artificial intelligence in surgery ( Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

More from ecancer